AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015


 ET | Source: Arno Therapeutics Inc.

FLEMINGTON, N.J., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that four abstracts supporting the ongoing development of AR-12 as a broad-spectrum, antimicrobial drug have been accepted for presentation, one of which will be a podium presentation, at the upcoming Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) / International Congress of Chemotherapy and Infection (ICC) 2015, jointly hosted by the American Society for Microbiology (ASM) and International Society of Chemotherapy (ISC), and being held September 17-21, 2015 in San Diego, CA.   

During the podium presentation in the session "Current Research on Respiratory and Other Viruses" on Saturday, September 19, Stefan Proniuk, Chief Development Officer of Arno Therapeutics will present an in vitro inhibition of chikungunya virus replication by AR-12. In addition, Arno will present a poster discussing AR-12 as the lead compound of a potential new class of antifungal agents with a novel mechanism of action. Two preclinical studies will also be presented by investigators from the Ohio State University, one discussing a preclinical study of AR-12 as an antifungal agent and another poster discussing AR-12 as a potential new therapeutic agent for tularemia.

Antifungal name: 

Date of article/Start date of trial: 

Friday, July 15, 2016
New antifungal drugs